Notably, the enrichment of PTEN mutations and increased PI3K-AKT pathway activity are associated with immunosuppressive mechanisms during ICB treatment of GBM and appear to be enriched in the non-responders (12). This evidence concerns the gene AKT1 and glioblastoma.